Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sorting and Selecting Cancer Cells by Their Motility Will Advance Understanding of Metastatic Processes

By LabMedica International staff writers
Posted on 03 Jun 2015
In order to develop a better understanding of the mechanisms that cause some cancer cells to break away from the primary tumor and migrate to other parts of the body, a team of cancer researchers has created an instrument for sorting and selecting cancer cells based on their motility.

Tumor cell migration toward and into capillaries is an early and key event in cancer metastasis, yet not all cancer cells are imbued with the same capability to do so. More...
This heterogeneity within a tumor is a fundamental property of cancer.

Conventional in vitro migration platforms have so far related to cell populations as an aggregate, which has led to a masking of intrinsic differences among cells. While some migration assays have reported the ability to resolve single cells, these platforms did not provide for selective retrieval of the distinct migrating and non-migrating cell populations for further analysis.

Therefore, to study the intrinsic differences in cells responsible for chemotactic heterogeneity, investigators at the University of Michigan (Ann Arbor, USA) developed a single-cell migration platform so that individual cells’ migration behavior could be studied and the heterogeneous population sorted based upon chemotactic phenotype. Furthermore, after migration, highly chemotactic and non-chemotactic cells were retrieved and proved viable for later molecular analysis of their differences.

In addition, as described in a paper published in the May 18, 2015, online edition of the journal Scientific Reports, the investigators modified the migration channel to resemble lymphatic capillaries to better understand how certain cancer cells are able to move through geometrically confining spaces.

"This work demonstrates an elegant approach to the study of cancer cell metastasis by combining expertise in engineering and biology," said senior author Dr. Euisik Yoon, professor of electrical engineering, computer science, and biomedical engineering at the University of Michigan. "In past decades, engineers have developed biological tools with better resolution, higher sensitivity, selectivity, and higher throughput. However, without compelling applications, these engineering tools have little practical relevance. The goal of our lab is to develop tools that can be widely disseminated to the biology community to eventually impact clinical care for patients."

Related Links:

University of Michigan



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.